Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a net profit attributable to the parent company of between 20 million to 30 million yuan, representing a year-on-year decrease of 90.05% to 93.37% [1] Financial Performance - The expected non-net profit is projected to be between 65 million to 85 million yuan, reflecting a year-on-year decrease of 70.42% to 77.38% [1] - The decline in performance is primarily attributed to reduced domestic market demand due to industry policies, leading to decreased revenue and gross margin [1] Business Operations - Despite the challenges in the domestic market, the company's overseas business is experiencing stable growth [1] - The company has achieved full coverage of IVDR CE certification for its eight preoperative series of reagents [1] Product Development - The company has made significant advancements in product research and development, expanding its domestic chemiluminescence product menu to 180 items [1] - Several products have received certification or authorization, indicating a strong pipeline of new offerings [1]